Share on StockTwits

Sagent Pharmaceuticals (NASDAQ:SGNT) Director Robert J. Flanagan unloaded 16,000 shares of the stock in a transaction dated Thursday, August 28th. The stock was sold at an average price of $27.19, for a total transaction of $435,040.00. Following the completion of the sale, the director now directly owns 6,996 shares of the company’s stock, valued at approximately $190,221. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

A number of analysts have recently weighed in on SGNT shares. Analysts at RBC Capital raised their price target on shares of Sagent Pharmaceuticals from $20.00 to $27.00 in a research note on Thursday, July 31st. They now have a “sector perform” rating on the stock. Separately, analysts at JPMorgan Chase & Co. raised their price target on shares of Sagent Pharmaceuticals from $24.00 to $27.00 in a research note on Thursday, July 31st. They now have a “neutral” rating on the stock. Finally, analysts at Jefferies Group raised their price target on shares of Sagent Pharmaceuticals from $23.00 to $25.00 in a research note on Thursday, July 31st. They now have a “hold” rating on the stock. Six investment analysts have rated the stock with a hold rating, Sagent Pharmaceuticals has a consensus rating of “Hold” and an average target price of $26.67.

Sagent Pharmaceuticals (NASDAQ:SGNT) traded up 2.69% during mid-day trading on Friday, hitting $27.82. The stock had a trading volume of 114,566 shares. Sagent Pharmaceuticals has a one year low of $17.49 and a one year high of $28.73. The stock has a 50-day moving average of $25.85 and a 200-day moving average of $23.27. The company has a market cap of $887.3 million and a price-to-earnings ratio of 59.54.

Sagent Pharmaceuticals (NASDAQ:SGNT) last issued its quarterly earnings data on Wednesday, July 30th. The company reported $0.09 earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.01) by $0.10. The company had revenue of $69.20 million for the quarter, compared to the consensus estimate of $67.14 million. Sagent Pharmaceuticals’s revenue was up 16.1% compared to the same quarter last year. On average, analysts predict that Sagent Pharmaceuticals will post $0.26 earnings per share for the current fiscal year.

Sagent Pharmaceuticals, Inc (NASDAQ:SGNT) is an injectable pharmaceutical company, which develops and sources products, which the Company sells in the United States.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.